as per HMRN 2004-14, 2 with expected cases per year of 38730 for all haematological neoplasms and the reported median age at diagnosis is 70.8 years. 2 There have been advances in the treatment of haematological cancers, and it has led to improvement in survival, with an overall 5-year relative survival of 69.2%. 2 The improvement in survival with HM has put emphasis on the long-term effects of the disease and its treatments. There is evidence that health-related quality of life (HRQoL) of HM patients is greatly affected in both short term and long term. [3] [4] [5] [6] [7] [8] Difficulty with physical and psychosocial activity, living with uncertainty, worrying about future and relapse and impact on work life are evident in survivors of HM and bone marrow transplant. 3, [9] [10] [11] [12] The high-dose chemotherapy has a detrimental effect on many patients' bone marrow which is usually followed by bone marrow transplant (BMT), 13, 14 and this might have further complications such as graft-versus-host disease (GVHD). [15] [16] [17] Most of these studies which focus on identifying the quality-of-life (QoL) issues important to HM patients and evaluating their QoL have used the standard HRQoL instruments from the shelf for such purpose. There are a wide range of HRQoL instruments which are currently used in haematology to understand such impact, some are general to oncology, and others are specific to a type of haematological disease. Furthermore, some of the instruments which are developed and used for patients with solid tumours (ST) are also used in haematology. However, the most important questions are as follows: Are the quality-of-life issues, the impact of the disease and treatment and patient needs the same for patients with ST and HM? There is evidence suggesting that this is not the case. In general, the psyche of patients with HMs is different to that of patients with ST, and consequently, the conceptual model for the two would be different based on the fundamental philosophical notion of "normative standard." Thus, conceptually, patients make assessment/perception of their HRQoL with reference to their "normative standard" to which no one except patients themselves have access. For example, compared to solid tumours, patients with HMs: experience significant challenges with emotional/psychological disturbances [18] [19] [20] [21] ; experience prolong periods of neutropenia 22 ; have more frequent visit to intensive care unit or inpatients 19 ; are more likely to die in the hospital, and use intensive care during the last days of their life 23, 24 ; receive less information on sexual side effects of the treatment as well as treatment information 25 ; and are much less likely to be referred to the specialist palliative care later in the course of their illness. [26] [27] [28] Moreover, most of these instruments have been developed and validated for use in clinical trials, but the need of patient-reported outcome (PRO) measures in clinical practice has been reported. 29, 30 The PROs intended for such purpose can be used to assist in clinical care and gather valuable information related to patient experiences. The wide range of HRQoL instruments makes it challenging for the clinical care team to select, use and understand the scoring system and finally interpret the results.
Several systematic reviews have been conducted in the past which only describes the HRQoL issues important to patients with different HMs, [31] [32] [33] but none except Osborne et al (2012) have assessed the content of the HRQoL instruments against these HRQoL issues. Furthermore, no systematic review has provided a comprehensive conceptual framework of the HRQoL themes and sub-themes for patients with HMs. According to FDA, the adequacy of any HRQoL instrument depends on its characteristics including conceptual framework.
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The aim this systematic review was to identify the important HRQoL components to patients with HM required for developing a conceptual framework based on published literature to sup- 
| ME THODS
This systematic review focuses on the primary studies which have used semi-structured/structured interviews or surveys to identify issues important to HM patients and other studies describing the results of psychometric testing of the instruments currently used to assess the HRQoL in different HMs.
| Search strategy
The literature search was carried out for both published and unpublished studies. A 3-step search strategy was used. For the first step, search was carried out using MEDLINE, followed by additional search using SCOPUS with the same search string. In the third step, the reference list of all identified and included papers were scanned for any additional studies, followed by the manual search of the articles in the last step. The literature search was confined to only two databases due to limited access to other databases. All the studies in English languages, involving adult (18+ age) patients and published between 1 January 1990 and 31 December 2016 were considered for the inclusion in the review. The search terms were kept as inclusive as possible to identify all the relevant studies. Since there are wide range of different haematological malignancies with wide range of published and ongoing research in haemato-oncology, it might result in a number of irrelevant studies to the current research question. Hence, to narrow down the search period to a more relevant timeline and to process the most relevant identified studies, Osborne et al 35 paper was used as a guide. The publication period of 26 years considered for this systematic review is defined based on the reference list from Osborne et al. 35 
| Search terms
The search terms were finalised after discussion between the two reviewers (PG and YK) and were kept as inclusive as possible for the identification of the studies ( Figure 1 ). The term "clinical practice"
refers to any consultation activity and provision of care that take place routinely in an outpatient setting.
| Study identification & screening
In the systematic review, all the experimental and epidemiological studies focusing on HM patients' HRQoL were included irrespective of the study design. A novel approach used by Osborne et al 35 in a review published for myeloma patients was used to screen every identified study for two different sets of inclusion and exclusion criteria. The two reviewers agreed on the two sets of the inclusion and the exclusion criteria ( Figure 1 ). The "issues criteria" were designed to identify the studies which focus only on the areas which are reported important by the patients themselves rather than using any standardised instruments. Studies using only inductive methods (qualitative) were included. The "instruments criteria" were designed to focus on the studies which describe the development and measurement properties of the instruments with respect to different domains rather than focus on any single construct such as physical ability. Studies with a sample consisting >25% of patients with HM were included. This means studies with a mixed sample with different type of cancers (breast cancer, lung cancer, pancreatic cancer, etc.) were included only if more than 25% of the total sample were diagnosed with any haematological malignancy. The systematic stepwise approach of inclusion and exclusion of the studies was adopted as per PRISMA guidelines. 36 
| Data collection and synthesis
The standardised data extraction tool from Cochrane collaboration was adopted for extracting the data. All the information was extracted by two reviewers (PG and YK) with consensus. Any unresolved discrepancies were then discussed with the third reviewer, the adjudicator (SS), to reach consensus. A summary table of all the articles identified as per issues criteria was developed to summarise the HRQoL issues reported by the patients in such studies. The quality assessment of all the articles included under "issue criteria" was carried out using a critical appraisal tool developed by Hawker et al 37 for qualitative studies. Hawker's checklist was used to rate the nine components (abstract and title; introduction and aims; method and data; sampling; data analysis; ethics and bias; results; transferability or generalisability; and implications and usefulness: How important are these findings to policy and practice?) for each article as "good"
(score 3), "fair" (2), "poor" (1), or "very poor" (0), with maximum possible score of 27 for each article where higher score mean reflects better quality. The Hawker's tool was chosen because it provides clear description of ratings, that is, "good," "fair," "poor" and "very poor," and has been designed to assess quality of studies covering a variety of research paradigms. All the issues identified were then divided into two broad categories after reaching consensus between the two reviewers: "HRQoL issues" and "Signs and Symptoms" (including disease-related symptoms and treatment side effects). The classification of the identified HRQoL issues in the literature into respective themes and sub-themes was entirely based on the underlying theoretical construct. The themes and sub-themes generated were discussed among all three reviewers to reach consensus.
A second summary table of all the articles included in the instruments criteria was developed to summarise the QoL instruments and their measurement and psychometric properties for use in patients with HM.
| RE SULTS
The two databases search resulted in 39 656 articles. All the identified studies were screened by two reviewers (PG and YK) against two set of criteria. After a systematic inclusion and exclusion of articles, 24 articles were included as per the issues criteria and 57
articles were included as per the instruments criteria. The PRISMA flow chart, presented in Figure 2 , shows the different steps of identification and screening of the selected articles and reasons of exclusion. Three articles reporting development and validation of on myelodysplastic syndrome (MDS), leukaemia and myeloma-specific instrument (QoL-E, Fact-Leu and EORTC-MY24) were included in both sets.
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F I G U R E 1 Outline of methods and inclusion and exclusion criteria
| HRQoL issues reported important by patients
Twenty-four articles were identified meeting the inclusion/exclusion criteria, using inductive method to identify HRQoL issues reported as important by patient with HMs. A total of six articles focused on leukaemia patients, ten on multiple myeloma (MM), six on patients with HMs undergone BMT, two on lymphoma and two MDS patients. A total of 14/24 articles focused on exploring lived experience with disease, three on lived experience with SCT, two on response and psychological impact of intensive treatment, one on sexuality post-SCT and three on development of disease-specific instrument. A total of fifty different disease-related symptoms and treatment side effects were identified from the selected articles and classified as "Signs and Symptoms" (Table 1) . Overall, 21 HRQoL issues were reported important by the patients with different HMs (Table 1 ). The most highly reported disease-and treatment-related symptoms across all included studies were as follows: tiredness; fatigue; feeling ill; nausea; and weakness. The most highly reported HRQoL life issues were as follows: impact on daily life; living with uncertainty; and financial impact.
Almost all the identified studies used purposive sampling for data collection without using sampling to redundancy approach, which is an important consideration in the qualitative research,
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except three articles where inpatients were interviewed until saturation was achieved.
39,42,43

| HRQoL instruments identified
Thirty different HRQoL instruments were identified from 57 included articles as per instruments criteria. Of these, four were 
| Content validity of HRQoL instruments
The ability of each instrument to capture the quality-of-life issues identified from the 24 qualitative studies is shown in 
| Psychometric properties of the identified HRQoL instruments
A summary of the psychometric properties of the identified HRQoL instruments is presented in 
| Instrument for lymphoma patients
FACT-G and its lymphoma module FACT-Lym have been identified for lymphoma patients. One study reporting the psychometric properties of the FACT-Lym was carried out only with non-Hodgkin lymphoma patients from USA. It is also noteworthy that no correlation was found between FACT subscales and social desirability scale.
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Validation of FACT-G was carried out with mixed patient groups. No instrument has been validated to be used in daily clinical practice.
Ceiling effect has been reported for 4 items from FACT-G scale (nausea, feeling ill, forced to spend time in bed and losing hope in fight against illness). 
| Instruments for leukaemia patients
Out of 23 studies reporting psychometric properties of EORTC-QLQ-C30, only five studies recruited patients with leukaemia (acute and chronic), the majority of these patients were diagnosed with AML. One study focused 100% on AML patients. 69 Only one study has been identified reporting the psychometric properties 3. Uncertainty and inability to plan things in advance Hard to set up daily routine at home as they have to go to the hospital for several courses of inpatient therapy. During outpatient treatment, the monthly course of therapy means an interruption of their everyday routine such as work, family, household task. Uncertainty about long-term remission is another threat to a patient's psychological well-being.
Leading a normal life
Leading a plain, ordinary life, back to daily routine is a highly desired aim for most patients.
Fear of relapse 6. Emotional support
Relying for emotional support not only on family, but also from nurses and medical staff.
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Chronic leukaemia 
Difficulties after transplant
Coping physical symptoms, coping with family, frustration on inabilities to perform/ function in daily life, returning to work, and fear of dying and getting ill again, infertility, problems with social life, increased dependency on others, planning for future, coping with memories and dealing with financial restrictions
After coming home
Future concerns related to health, relapse, concerns on Long-term effects of transplant, financial concerns and infertility, planning about future, concerns about the normalisation process and coping with family. 
Recuperation
Strengthened body and spirit.
Reflection/New Existence
Changed body (weight gain, short-term memory loss, insomnia, fatigue and painful neuropathy), less hope for future treatments, enduring threat of relapse, anticipating loss, acceptance, identifying resilience in oneself, strengthened connection to others, living while dying. 
Living with Uncertainty
Not being able to plan things, Impact of day-to-day life, uncertainty due to treatment and disease, worrying about test results.
Intuitive knowing
Knowing that disease has relapsed before being told by the consultant.
Maintenance of normalcy
Living a normal life appeared to be vital as a means of preventing cancer becoming dominant.
Adjustment to illness
Adjustment to illness and managing their lives accordingly, support from family members, withholding information about disease to protect family and friends, physical and psychological stress, increased dependency on others for daily activities, lack of mobility, psychological distress and depression, anxiety and social isolation.
Hope
Dealing with uncertainty, belief in an afterlife, spiritual beliefs, and hope for new treatment provided an 'illusion of safety. Not active as used to, frustration, rely on others, not able to do self-care and care for family, transition from abled to 'disabled', future concerns related to health problems, constipation, losing height, anxiety about relapse, worrying about protein levels in blood/urine, uncertainty about future.
Effects of myeloma in daily life
Tiredness, back pain, long-term effects-cataracts, neuropathy, hearing loss and graft-vs-host disease affecting legs., lack of energy & mobility, inability to do housework, inability to walk far or play with grandchildren, being housebound, not socialising, given up work as a result of illness, could not cope with demands of the previous job, diagnosis affecting partner's life, 3. Practical, functional and emotional coping use of aids to maintain independence and functional well-being or ease of symptoms, housebound, refused to use wheelchair because it is embarrassing, eager to gather knowledge about myeloma, maintaining healthy body, being active in order to stay well for children, difficulty in self-management, covering (concealing) and, not discussing illness with friends, cheating in hospitals by wearing heavy clothes while weighing. Psychological coping mechanism like avoiding, denial, staying positive, using comparisons with others, normalising, distraction and stoicism.
Unmet needs
Limited expressed needs, limited help from outside agencies, lack of continuity of care, seeing the person in the patient. • Impact of pain on family and leisure activities • Impact of fatigue on everyday activities.
• Impact of fear of injury on leisure activities.
• Impact on independence. Wife or partner has become caretaker.
• Impact of symptoms-fear of fractures and restricted sports activities and other leisure activities. travel was affected, depression.
• Impact of MM treatment-Clinic visits (frequency and commuting). Blood test regularly even if travelling and finding a testing centre.
• Mode of administration-IV every month, scares on arms.
• Treatment burden-Inconvenience, Financial, mode of administration, monitoring
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TA B L E 3 (Continued) 
TA B L E 4 Summary of psychometric properties of the identified HRQoL instruments
Test-retest reliability
Pearson's correlation coefficient r = 0.71 (P < 0.001) showed strong consistency over time.
Internal consistency
Over all Cronbach's alpha = 0.85 (P < 0.01 (n = 239, 100% MM) 60, 61 (n = 1956, 10% lymphomas, 22% myeloma) 62 (n = 92, 100% MM)
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(n = 12. 100% MM) 63 (n = 202, 100% MM) 64 (n = 22, 4.5% HL, 18% NHL, 27% AML, 54% MM) 65 (n = 521, %100 MM) 66 (n = 745, 100% MM) 67, 68 Trial data: German (n = 101, 100% AML) 69 Trial data: USA HSCT patients (n = 20 at baseline, n = 17 post-transplant 57 Trial data: USA (n = 132, 100% MM) 70 
Convergent and divergent validity
Correlation between item and own scale >0.3 (0.3-0.7). Good discriminant validity in majority of scales 50 The 0.4 item scale correlation criteria were satisfied. Good association with MDASI-MM for physical, role, cognitive, social and emotional-functioning subscales (all P < 0.001).
70
Construct validity
For physical functioning, patients had decreased score from 67% to 48% for 10th percentile of the reference population and 43% to 20% for global QoL and for pain 46% had higher scores.
56
All subscales significantly impaired compared to reference population. 
Convergent and divergent validity
The correlation between an item and its own hypothesised scale was higher than 0.4 for all the subscales except side effects of treatment which ranged from 0.17 to 0.72. At the baseline. At the follow-up, the correlation was again higher than 0.4 for all the scales accept the improved correlation of 0. 
Internal consistency
Cronbach's alpha >0.7 for all scales 50 Cronbach's alpha >0.7 for all scales
49
Floor and ceiling effects mean ceiling values of 100. Functional scale with >50% of patients with ceiling effect. 50 Ceiling effect in body image scale.
Responsiveness
Disease symptoms (P −0.001) and body image (<0.0001) significantly decreased over time. The side effects of treatment increased significantly (P = 0.0036) 71 Sensitive to change in three scales after 1 mo (P > 0.01) 50 EORTC QLQ-HDC 
Convergent and divergent validity
Mean correlation between hypothesised scale and items >0.7 at all time lines for Health worries items and sexual functioning. For joint, muscle pain and 2 items for skin irritation had mean correlation of >0.4 at all items. 100% of items correlating higher or significantly higher with their hypothesised scale than with competing scale.
106
Criterion validity
Changes in score similar to EORTC-QLQ-C30 score changes 52
Internal consistency
At inclusion Cronbach's alpha >0.8 for health worries and sexual functioning.
Test-retest
Intra-class correlation coefficient was high for scales (0.96-1.00). For joint and muscle pain (0.59) and 0.62 for skin irritations.
106
Floor/ceiling effect All scales highly skewed with skin irritations, increased mucous production, soreness in mouth and worries about sterility responding at floor. 106 Floor effect for symptom and functional scales.
52
Responsiveness
Most changes found between baseline and 1 mo after transplantation with SRM ranging from 0.00 to 0.94.
106
Statistically significant score for functioning scales and some symptom scales from baseline to 1 mo after SCT.
52
TA B L E 4 (Continued) Content validity 20/32 items were retained and rest deleted after factor analysis.
83
Internal consistency
Cronbach's alpha >0.7 for both the factors.
83
Responsiveness
Significant difference between allograft and other two modalities (P < 0.0001) and factor two (P < 0.01). Four Subscales: physical well-being, social/ family well-being, emotional well-being and functional well-being.
Total 27 Items. Trial data: USA (n = 611, 100% lymphoma).
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Trial data: USA (n = 182, NHL (36%), HL (8%), CML (7%), AML (11%), ALL (2%), CLL (1%), MM (2%), MDS (0.5%). with statistical significance (all P < 0.001).
Construct validity
Performance status highly correlated with physical well-being (−0.58) and functional well-being subscale (−0.47).
108
Internal consistency
Cronbach's alpha >0.7 at all time points. Alpha >0.9 at all assessments for total scale. 81 Cronbach's alpha >0.9 at all time points. 39 Cronbach's alpha >0.7 at all three Times. 
Floor/ceiling effects
Floor effect less than 5% for all items in each of the three subgroups. Ceiling effect most apparent for nausea, feel ill, forced to spend time in bed, losing hope in fight against illness.
81
Sensitivity to change FACT-G total score and subscale scores demonstrated very good sensitivity to change in ECOG PS and LASA QoL. 81 Statistically significant results for the overall scale (P < 0.001).
108
FACT-LEU 39, 76 FACT-G and 27 item Leu subscale. 
Total 44 Items
Convergent and divergent validity
Construct validity
Lower mean scores of subjects from the Dutch general population of similar age and sex.
74
Lower mean scores compared to general population 75, 78 Criterion Validity
Total score SF-36 correlated with FACT-BMT (r > 0.4
76
Internal consistency
Cronbach's alpha ranged from 0.75 to 0.89 for all the scales.
74
Cronbach's alpha >0. 
Content validity
Developed by process involving physicians and patients
Concurrent validity
Statistically significant correlation with physical well-being, emotional well-being, functional well-being, overall, and treatment outcome index scores of FACT-G.
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Construct validity
Factor analysis showed many domains between the two instruments formed clusters.
40
Internal consistency
Cronbach's alpha >0.7 in all domains. 
Responsiveness
Significant lower depression (P = 0), fatigue (P = 0) and anger) P = 0) and vigour (P = 0).
69
TA B L E 4 (Continued) 
Structural validity
Bartlett's test of sphericity Cronbach's alpha = 0.89. The convergent validity correlations between the POMS-depression and the POMS total mood disturbance scores and the CES-D = 0.63. The negative affect scale had positive correlation at 0.44.
65
Internal consistency
Cronbach's alpha ranged from 0.78 to 0.91 for all the scales. 65 
TA B L E 4 (Continued)
of EORTC-QLQ-CML24. 82 No responsiveness, floor and ceiling effects have been reported. The validity results showed weak correlation between "satisfaction with care and information" and "social life" scales of QLQ-C30. 82 There was only one study identified for EORTC Leu scale, which was included as part of the EORTC GIMENA AML8A and MRC AML10 clinical trial. 83 Criterion validity, construct validity and MCID were not reported. For FACT-Leu, there were two studies which enrolled the US and Japanese leukaemia patients. The one conducted with the US patients included all type of leukaemia. 
| Generic instruments
The SF-36, SF-12, EQ-5D, 15D, LIP, QLI, SUNS, SF-SUNS, SeiQoL-DW, POMS and POMS-SF have been used in haematology as generic instruments. The highest evidence on measurement properties in haematological malignancy patients has been found for the SF-36.
One study reported correlation between the SF-26 and FACT-BMT scale. 76 Two studies identified for the SF-12 had patients only with MM; however, no detailed information for reliability and validity has been reported. Only one study reporting floor/ceiling effect, responsiveness and MCID in MM patients was identified for the 15D instrument. No information was found on reliability and validity of 15D in patients with HMs. The QLI instrument had also one study reporting internal consistency and MCID. One study identified for LIP could not be included because of unavailability of the full paper.
| D ISCUSS I ON
This systematic review has identified 24 studies using inductive Because there is no predefined sample size for qualitative research, it is of paramount importance to be able to capture all the issues important to these patients. Only 3 out of 24 studies reported sampling to redundancy, which raises the question of saturation point and content validity of the instruments which have been developed using the information from such qualitative research. 
| Recommendations for future research
The 30 
| Limitations
The limitations of this review include the following: focus on adult patients diagnosed with HM; and literature published in English language. The search string was developed to be as inclusive as possible. In addition, studies searched manually were also included; hence, the final list of included articles may vary slightly if carried out by a different researcher. Furthermore, the search did not include grey literature for additional studies such as letter to editors or dissertations.
However, PRISMA systematic review guidelines were strictly followed at each step and should be considered as strength of this review.
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